Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients

Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \< 10 years. The trial has two parts. In Part 1, the trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy. In Part 2, the trial will study two doses of SAT-3247 for an additional 9 months.

NCT Number	NCT07287189
Lead Sponsor	Satellos Bioscience, Inc.
Conditions	Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies
Enrollment	51 participants
Start Date	2025-12-08
Primary Completion	2027-03-31 (estimated)
Study Completion	2028-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-14